Safety and Efficacy Results from AGAVE-201 (Axatilimab Therapy in cGVHD)
Panelists discuss how axatilimab showed promising response rates in the AGAVE-201 trial, even in patients with graft-vs-host disease (cGVHD) who had failed other approved therapies.
Belumosudil and Axatilimab Data
This segment presents follow-up data from the ROCKstar study of belumosudil, showing:
- 74%-76% overall response rate across both dosing regimens (200 mg once or twice daily)
- Consistent responses across organ systems
- 57% failure-free survival at 12 months
- 25% of patients successfully discontinued all immunosuppression
- Common adverse events included fatigue, gastrointestinal symptoms, cough, and headache
The panel transitions to axatilimab data from the AGAVE-201 trial, which evaluated 3 different dosing regimens. The FDA-approved dose (0.3 mg/kg every 2 weeks) demonstrated:
- 74% overall response rate
- Median time to response of 1.4-1.7 months
- Median failure-free survival of approximately 11 months
- Main adverse events were laboratory abnormalities related to CSF1R blockade
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
